Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Casdozokitug by Coherus BioSciences for Renal Cell Carcinoma: Likelihood of Approval
Casdozokitug is under clinical development by Coherus BioSciences and currently in Phase II for Renal Cell Carcinoma. According to GlobalData,...
Casdozokitug by Coherus BioSciences for Solid Tumor: Likelihood of Approval
Casdozokitug is under clinical development by Coherus BioSciences and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
Casdozokitug by Coherus BioSciences for Hepatocellular Carcinoma: Likelihood of Approval
Casdozokitug is under clinical development by Coherus BioSciences and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData, Phase...
CHS-114 by Coherus BioSciences for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
CHS-114 is under clinical development by Coherus BioSciences and currently in Phase I for Head And Neck Squamous Cell Carcinoma...
CHS-114 by Coherus BioSciences for Solid Tumor: Likelihood of Approval
CHS-114 is under clinical development by Coherus BioSciences and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
Toripalimab by Coherus BioSciences for Solid Tumor: Likelihood of Approval
Toripalimab is under clinical development by Coherus BioSciences and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
Toripalimab by Coherus BioSciences for Melanoma: Likelihood of Approval
Toripalimab is under clinical development by Coherus BioSciences and currently in Phase II for Melanoma. According to GlobalData, Phase II...
Toripalimab by Coherus BioSciences for Soft Tissue Sarcoma: Likelihood of Approval
Toripalimab is under clinical development by Coherus BioSciences and currently in Phase I for Soft Tissue Sarcoma. According to GlobalData,...
Toripalimab by Coherus BioSciences for Chondrosarcoma: Likelihood of Approval
Toripalimab is under clinical development by Coherus BioSciences and currently in Phase I for Chondrosarcoma. According to GlobalData, Phase I...
Toripalimab by Coherus BioSciences for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval
Toripalimab is under clinical development by Coherus BioSciences and currently in Phase II for Esophageal Squamous Cell Carcinoma (ESCC). According...
Toripalimab by Coherus BioSciences for Soft Tissue Sarcoma: Likelihood of Approval
Toripalimab is under clinical development by Coherus BioSciences and currently in Phase I for Soft Tissue Sarcoma. According to GlobalData,...
Toripalimab by Coherus BioSciences for Chondrosarcoma: Likelihood of Approval
Toripalimab is under clinical development by Coherus BioSciences and currently in Phase I for Chondrosarcoma. According to GlobalData, Phase I...
Risk adjusted net present value: What is the current valuation of Coherus BioSciences's Casdozokitug?
Casdozokitug is a monoclonal antibody commercialized by Coherus BioSciences, with a leading Phase II program in Squamous Non-Small Cell Lung...